Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monalizumab or Placebo Plus Cetuximab in Recurrent/Metastatic SCCHN After Immune Checkpoint Inhibitor
2024-511813-39-00Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Monalizumab + cetuximab with Placebo + cetuximab (2 arms). Primary endpoint: Overall survival (primary). Started Jun 2024; status: completed.
02
Drugs
monalizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2024-511813-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511813-39-00.